<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796497</url>
  </required_header>
  <id_info>
    <org_study_id>ONDAN-1</org_study_id>
    <nct_id>NCT00796497</nct_id>
  </id_info>
  <brief_title>Ondansetron in Treatment Resistant Obsessive Compulsive Disorder (OCD)</brief_title>
  <official_title>Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Neuroscience, Florence, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Neuroscience, Florence, Italy</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given that 5-HT3 receptors are indirect inhibitors of cortico-mesolimbic DA release, the
      5-HT3 receptor antagonist ondansetron augmentation might potentially have efficacy in the
      treatment of resistant Obsessive Comulsive Disorder (OCD) patients on combined SRIs and
      antipsychotics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      METHOD: Fourteen patients with a DSM-IV diagnosis of treatment resistant OCD, under stable
      treatment with SSRI's and neuroleptic augmentation will enter an 12-week single blind trial
      of ondansetron initiated at a dose of 0.25 mg twice daily for 6 weeks, that will be titrated
      to 0.5 mg twice daily for 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale-Brown Obsessive Compulsive Scale (Y-BOCS)</measure>
    <time_frame>6th 12th week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical global impression (CGI)</measure>
    <time_frame>6th e 12th</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>ondansetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ondansetron</intervention_name>
    <description>ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.</description>
    <arm_group_label>ondansetron</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. adults aged 18 to 55

          2. a Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) score of ≥ 20 after ≥ 12 weeks of
             treatment with an established effective dose of an Selective Serotonin Reuptake
             Inhibitors or clomipramine and after ≥ 10 weeks of augmentation treatment with
             antipsychotics (risperidone at least 2 mg/day quetiapine at least 150 mg/day;
             olanzapine at least 5mg/day; haloperidol titrated at least 10 mg/day; aripiprazole at
             least 10 mg/day)

        Exclusion Criteria:

          1. a history of alcohol or substance abuse

          2. current severe depressive symptoms, bipolar disorder, panic disorder, schizophrenia,
             or other psychiatric conditions

          3. heart disease, arrhythmia, liver problems, including cirrhosis, seizures, glaucoma or
             serious medical disease

          4. hoarding as only Obsessive Compulsive symptom

          5. women of childbearing potential not using a medically acceptable contraceptive method.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Pallanti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto di Neuroscienze</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Neuroscience</name>
      <address>
        <city>Florence</city>
        <zip>50122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hewlett WA, Schmid SP, Salomon RM. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J Clin Psychiatry. 2003 Sep;64(9):1025-30.</citation>
    <PMID>14628977</PMID>
  </reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <last_update_submitted>February 23, 2011</last_update_submitted>
  <last_update_submitted_qc>February 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Stefano Pallanti</name_title>
    <organization>Institute of Neuroscience</organization>
  </responsible_party>
  <keyword>Obsessive Compulsive Disorder</keyword>
  <keyword>5-ht3</keyword>
  <keyword>ondansetron</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

